Photobiomodulation in Head and Neck Cancer-Related Chronic Lymphedema

Recruiting now · Not applicable · Has a placebo group

Conditions studied: Head and Neck Cancer, Lymphedema of the Head and Neck

In brief

The U.S. Food and Drug Administration approved photobiomodulation therapy (PBMT) as a treatment for breast cancer-related arm lymphedema (BCRL) in 2006. The investigators conducted two pilot clinical trials. Results demonstrated the feasibility, acceptability, and preliminary efficacy of PBMT for the treatment of chronic lymphedema in head and neck cancer (HNC) survivors. The objective of this study is to further investigate and confirm the positive effects of PBMT on HNC-related chronic lymphedema.

Key facts

Study ID
NCT06837480
Run by
Abramson Cancer Center at Penn Medicine
People needed
150
Starts
2026-01-15
Expected to finish
2029-11-30
Last updated by the study team
2026-06-23

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.